RETROSPECTIVE REVIEW OF HIGH-RISK ADOLESCENTS ELIGIBLE FOR PRE-EXPOSURE PROPHYLAXIS (PREP) THERAPY FOR HIV

Purpose: In 2014 in the US, adolescents aged 13-24 made up 22% of all new HIV infections. In July 2012, the FDA approved Truvada as preexposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV in high-risk patients. The Adolescent Trials Network has completed 2 pilot studies to assess...

Ausführliche Beschreibung